Myeloma and AL Amyloidosis

Subscribe to
our newsletter!

Subscribe here

Q&As on myeloma

Infection risk with myeloma and myeloma treatments

This Q&A covers the most frequently asked questions about infections in myeloma and myeloma treatments. (September 2025)

Reducing infection risk in myeloma

This Q&A covers the most frequently asked questions related ways to reduce risk of infections related to myeloma and myeloma treatments. (September 2025)

Cytogenetics and risk testing in myeloma

This Q&A covers the most frequently asked questions related to cytogenetics and risk testing in myeloma. (February 2025)

AL amyloidosis vs myeloma

This Q&A covers the most frequently asked questions related to the differences between AL amyloidosis and myeloma. (March 2023)

Living with AL amyloidosis

This Q&A covers the most frequently asked questions related to living with AL amyloidosis. (March 2023)

Diagnosis, treatment and monitoring of AL amyloidosis

This Q&A covers the most frequently asked questions related to diagnosis, treatment and monitoring of AL amyloidosis. (March 2023)

CAR T-cell therapy side effects

This Q&A explains the side effects that can occur during CAR T-cell therapy. (March 2023)

Minimal Residual Disease (MRD)

MRD stands for Minimal Residual Disease. Find the answers to the most frequently asked questions by patients about MRD. (March 2023)

Chimeric Antigen Receptor T cell (CAR-T) therapy

CAR-T is a form of immunotherapy currently approved and under investigation for the treatment of myeloma. Find the answers to the most frequently asked questions by patients about CAR-T. (June 2022)

SARS-CoV-2 (COVID-19) Vaccination and Treatment

The SARS-CoV-2 (COVID-19) pandemic raised many questions, especially around vaccination. You can find the answers to the most frequently asked questions about the current approved vaccines and treatments in Europe. (February 2022)

European Union (EU) Funded Projects

The European Union is a political and economic union of 27 countries designed to enhance social cohesion among its members. You can find the answers to the most frequently asked questions about the funded projects in this Q&A. (July 2021)

Health Technology Assessment (HTA)

This Myeloma Patients Europe Q&A explains the role of Health Technology Assessment (HTA) in Europe. It covers what HTA is and provides a general picture of how it works within the context of reimbursement systems. (March 2018)

H2020 MMPredict

Horizon 2020 is a large-scale EU Research and Innovation Programme. It funds a wide range of different projects relating to science, innovation and tackling societal challenges. This is a Q&A explaining MMpredict and the role of the project consortium in further detail.